These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 27812884)

  • 1. Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.
    Tyulyandina A; Harrison D; Yin W; Stepanova E; Kochenkov D; Solomko E; Peretolchina N; Daeyaert F; Joos JB; Van Aken K; Byakhov M; Gavrilova E; Tjulandin S; Tsimafeyeu I
    Invest New Drugs; 2017 Apr; 35(2):127-133. PubMed ID: 27812884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models.
    Tsimafeyeu I; Ludes-Meyers J; Stepanova E; Daeyaert F; Khochenkov D; Joose JB; Solomko E; Van Akene K; Peretolchina N; Yin W; Ryabaya O; Byakhov M; Tjulandin S
    Eur J Cancer; 2016 Jul; 61():20-8. PubMed ID: 27136102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic Activity of Alofanib, an Allosteric Inhibitor of Fibroblast Growth Factor Receptor 2.
    Khochenkov DA; Solomko ES; Peretolchina NM; Ryabaya OO; Stepanova EV
    Bull Exp Biol Med; 2015 Nov; 160(1):84-7. PubMed ID: 26597690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Modeling, de novo Design and Synthesis of a Novel, Extracellular Binding Fibroblast Growth Factor Receptor 2 Inhibitor Alofanib (RPT835).
    Tsimafeyeu I; Daeyaert F; Joos JB; Aken KV; Ludes-Meyers J; Byakhov M; Tjulandin S
    Med Chem; 2016; 12(4):303-17. PubMed ID: 26732115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer.
    Cole C; Lau S; Backen A; Clamp A; Rushton G; Dive C; Hodgkinson C; McVey R; Kitchener H; Jayson GC
    Cancer Biol Ther; 2010 Sep; 10(5):495-504. PubMed ID: 20595807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
    Garrett LA; Growdon WB; Rueda BR; Foster R
    J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion.
    Kawano S; Kawada MI; Fukushima S; Arai Y; Shibata T; Miyano SW
    Anticancer Res; 2024 Jun; 44(6):2393-2406. PubMed ID: 38821585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer.
    Tsimafeyeu I; Statsenko G; Vladimirova L; Besova N; Artamonova E; Raskin G; Rykov I; Mochalova A; Utyashev I; Gorbacheva S; Kazey V; Gavrilova E; Dragun N; Moiseyenko V; Tjulandin S
    Invest New Drugs; 2023 Apr; 41(2):324-332. PubMed ID: 36907947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model.
    Taurin S; Yang CH; Reyes M; Cho S; Coombs DM; Jarboe EA; Werner TL; Peterson CM; Janát-Amsbury MM
    Int J Gynecol Cancer; 2018 Jan; 28(1):152-160. PubMed ID: 28953502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
    Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
    Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts.
    Teicher BA; Menon K; Alvarez E; Shih C; Faul MM
    Invest New Drugs; 2002 Aug; 20(3):241-51. PubMed ID: 12201487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
    Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Natali PG; Bagnato A
    Can J Physiol Pharmacol; 2010 Jun; 88(6):676-81. PubMed ID: 20628434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
    Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344.
    Wickstroem K; Hagemann UB; Kristian A; Ellingsen C; Sommer A; Ellinger-Ziegelbauer H; Wirnitzer U; Hagelin EM; Larsen A; Smeets R; Bjerke RM; Karlsson J; Ryan OB; Wengner AM; Linden L; Mumberg D; Cuthbertson AS
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):410-422. PubMed ID: 31255687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
    Gao Y; Shan N; Zhao C; Wang Y; Xu F; Li J; Yu X; Gao L; Yi Z
    Int J Clin Exp Pathol; 2015; 8(5):4923-32. PubMed ID: 26191185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
    Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
    J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
    Rosanò L; Di Castro V; Spinella F; Nicotra MR; Natali PG; Bagnato A
    Mol Cancer Ther; 2007 Jul; 6(7):2003-11. PubMed ID: 17620430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.
    Byron SA; Loch DC; Pollock PM
    Int J Gynecol Cancer; 2012 Nov; 22(9):1517-26. PubMed ID: 23060048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.
    Lengyel E; Litchfield LM; Mitra AK; Nieman KM; Mukherjee A; Zhang Y; Johnson A; Bradaric M; Lee W; Romero IL
    Am J Obstet Gynecol; 2015 Apr; 212(4):479.e1-479.e10. PubMed ID: 25446664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor.
    Takeda M; Arao T; Yokote H; Komatsu T; Yanagihara K; Sasaki H; Yamada Y; Tamura T; Fukuoka K; Kimura H; Saijo N; Nishio K
    Clin Cancer Res; 2007 May; 13(10):3051-7. PubMed ID: 17505008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.